Neuraura develops wearable bioelectronic devices designed to support personalized management of chronic conditions such as polycystic ovary syndrome (PCOS). The company’s platform combines non-invasive micro-electrode sensing with targeted electrical stimulation in a compact wearable form factor. Its approach focuses on modulating physiological pathways involved in hormonal and metabolic regulation. Neuraura positions its technology within clinical and digital health care contexts.

The technology integrates micro-electrodes that interface with peripheral bioelectrical signals and deliver controlled stimulation protocols. By sensing physiological activity and applying stimulation, the system aims to influence regulatory mechanisms associated with chronic symptoms. This bioelectronic framework supports adaptive and individualized intervention rather than fixed treatment regimens. The wearable design emphasizes usability and continuity of care outside traditional clinical settings.

Neuraura targets women’s health applications, with an initial focus on relieving PCOS-related symptoms through personalized bioelectronic therapy. The platform is intended to complement existing medical care rather than replace pharmacological treatment. Its positioning reflects growing interest in bioelectronic approaches for chronic condition management that combine personalization, wearability, and continuous support.